http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
고경남,한정우,최형수,강형진,이지원,유건희,성기웅,구홍회,홍경택,최정윤,강성한,김혜리,임호준,한승민,유철주,백희조,국훈,박경미,양유진,임영탁,김성구,이재욱,정낙균,조빈,박미림,박현진,박병규,이준아,박준은,김순기,김지윤,김효선,마영은,박경덕,박상규,박은실,심예지,유은선,유경하,유재원,임연정,윤회수,이미정,이재민,전인상,정혜림,최희원,원승현,The Korean 대한암학회 2023 Cancer Research and Treatment Vol.55 No.1
PurposeRenal tumors account for approximately 7% of all childhood cancers. These include Wilms tumor (WT), clear cell sarcoma of the kidney (CCSK), malignant rhabdoid tumor of the kidney (MRTK), renal cell carcinoma (RCC), congenital mesoblastic nephroma (CMN) and other rare tumors. We investigated the epidemiology of pediatric renal tumors in Korea.Materials and MethodsFrom January 2001 to December 2015, data of pediatric patients (0–18 years) newly-diagnosed with renal tumors at 26 hospitals were retrospectively analyzed.ResultsAmong 439 patients (male, 240), the most common tumor was WT (n=342, 77.9%), followed by RCC (n=36, 8.2%), CCSK (n=24, 5.5%), MRTK (n=16, 3.6%), CMN (n=12, 2.7%), and others (n=9, 2.1%). Median age at diagnosis was 27.1 months (range 0-225.5) and median follow-up duration was 88.5 months (range 0-211.6). Overall, 32 patients died, of whom 17, 11, 1, and 3 died of relapse, progressive disease, second malignant neoplasm, and treatment-related mortality. Five-year overall survival and event free survival were 97.2% and 84.8% in WT, 90.6% and 82.1% in RCC, 81.1% and 63.6% in CCSK, 60.3% and 56.2% in MRTK, and 100% and 91.7% in CMN, respectively (p < 0.001).ConclusionThe pediatric renal tumor types in Korea are similar to those previously reported in other countries. WT accounted for a large proportion and survival was excellent. Non-Wilms renal tumors included a variety of tumors and showed inferior outcome, especially MRTK. Further efforts are necessary to optimize the treatment and analyze the genetic characteristics of pediatric renal tumors in Korea.
고경남,유건희,임호준,성기웅,구홍회,김효선,한정우,윤종형,박현진,박병규,백희조,국훈,이준안,이재민,이광철,김순기,박미림,이영호,유철주,서종진 대한의학회 2016 Journal of Korean medical science Vol.31 No.8
This retrospective study investigated the clinical characteristics and outcomes of second malignant neoplasms (SMNs) in survivors of childhood cancer from multiple institutions in Korea. A total of 102 patients from 11 institutions who developed SMN after childhood cancer treatment between 1998 and 2011 were retrospectively enrolled. The most common primary malignant neoplasms (PMNs) were central nervous system (CNS) tumors (n = 17), followed by acute lymphoblastic leukemia (n = 16), non-Hodgkin lymphoma (n = 13), and osteosarcoma (n = 12). The most common SMNs were therapy-related myeloid neoplasms (t-MNs; acute myeloid leukemia [AML], 29 cases; myelodysplastic syndrome [MDS], 12 cases), followed by thyroid carcinomas (n = 15) and CNS tumors (n = 10). The median latency period was 4.9 years (range, 0.5-18.5 years). Among 45 patients with solid tumors defined as an SMN, 15 (33%) developed the lesion in a field previously subjected to radiation. The 5-year overall survival (OS) rate of patients with an SMN was 45% with a median follow-up time of 8.6 years. Patients with AML, MDS, and CNS tumors exhibited the poorest outcomes with 5-year OS rates of 18%, 33%, and 32%, respectively, whereas those with second osteosarcoma showed comparable outcomes (64%) to patients with primary counterpart and those with second thyroid carcinoma had a 100% OS rate. Further therapeutic efforts are recommended to improve the survival outcomes in patients with SMNs, especially in cases with t-MNs and CNS tumors.
고경남,임호준,김혜리,강형진,박경덕,신희영,안요셉,이지원,유건희,성기웅,구홍회,임영탁,박준은,박병규,박현진,서종진 대한의학회 2017 Journal of Korean medical science Vol.32 No.4
This multicenter, prospective trial was conducted to develop an effective and safe reinduction regimen for marrow-relapsed pediatric acute lymphoblastic leukemia (ALL) by modifying the dose of idarubicin. Between 2006 and 2009, the trial accrued 44 patients, 1 to 21 years old with first marrow-relapsed ALL. The reinduction regimen comprised prednisolone, vincristine, L-asparaginase, and idarubicin (10 mg/m2/week). The idarubicin dose was adjusted according to the degree of myelosuppression. The second complete remission (CR2) rate was 72.7%, obtained by 54.2% of patients with early relapse < 24 months after initial diagnosis and 95.0% of those with late relapse (P = 0.002). Five patients entered remission with extended treatment, resulting in a final CR2 rate of 84.1%. The CR2 rate was not significantly different according to the idarubicin dose. The induction death rate was 2.3% (1/44). The 5-year event-free and overall survival rates were 22.2% ± 6.4% and 27.3% ± 6.7% for all patients, 4.2% ± 4.1% and 8.3% ± 5.6% for early relapsers, and 43.8% ± 11.4% and 50.0% ± 11.2% for late relapsers, respectively. Early relapse and slow response to reinduction chemotherapy were predictors of poor outcomes. In conclusion, a modified dose of idarubicin was effectively incorporated into the reinduction regimen for late marrow-relapsed ALL with a low toxic death rate. However, the CR2 rate for early relapsers was suboptimal, and the second remission was not durable in most patients.
고경남,허준영,박성욱,조재현,김여호수아,황환철 대한전자공학회 2022 전자공학회논문지 Vol.59 No.10
국내 농업 분야 종사자의 수는 지속적으로 감소하고 있으며 기존 종사자의 고령화가 심화되고 있는 상황에서, 노동 생산성을 향상 시키기 위하여, ICT 기술을 농업 분야에 접목하는 작업이 다수 진행되고 있다. 이 중에서도 조작이 간편하고 안전성이 향상된 농기계의 개발과 공급을 위한 노력이 계속되고 있으며, 스마트 이앙기와 같이 농기계 시제품이 개발되고 있는 상황이다. 하지만 현재 발표되는 시제품들은 열린 공간에서 정해진 경로를 직진 주행과 회전 기능 위주로 개발되고 있어, 장애물이 있는 지역에서의 주행을 위하여 경로를 자동 계획하는 기능이나 돌발 장애물을 회피하는 기능은 미비한 상황이다. 이에 본 논문에서는 다목적 농업용 궤도차량에 사용할 수 있는 자율주행 모듈을 구현하였고 이를 소개하고자 한다. 자율주행 모듈은 지도 정보와 RRT* 알고리즘과 경로 평활화 기법 등을 사용하여 출발지에서 목적지까지의 경로를 생성한다. 생성된 경로는 주행 경로점들로 구성되며, 자율주행 모듈은, 차량이 주행할 때, 경로점들을 경유하도록 속도와 각도를 적절히 제어한다. 또한 주행 중에는 장애물의 존재 여부를 지속적으로 감지하고, 장애물이 감지된다면 이를 회피하여 목적지까지 계속 주행할 수 있도록 경로를 잠시 변경할 수 있다. 구현된 자율주행 모듈은 농업용 궤도차량에 탑재되어 주행 시험을 성공적으로 수행하였다.